Immune Pharmaceuticals Inc (IMNP.OQ)

IMNP.OQ on NASDAQ Stock Exchange Capital Market

1:48am IST
Change (% chg)

$0.01 (+2.16%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company's segment is acquiring, developing and commercializing prescription drug products. Its... (more)


Beta: 2.17
Market Cap(Mil.): $15.02
Shares Outstanding(Mil.): 10.58
Dividend: --
Yield (%): --


  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Immune Pharmaceuticals reports Q3 results

* Immune Pharmaceuticals announces third quarter 2017 financial results and provides a corporate update

15 Nov 2017

BRIEF-Immune Pharmac prices $18 mln public offering

* Immune Pharmaceuticals Inc announces pricing of $18,000,000 public offering of convertible preferred stock and warrants

19 Oct 2017

BRIEF-Immune Pharmaceuticals announces positive results from ongoing phase 2 trial of bertilimumab

* Immune Pharmaceuticals announces positive results from ongoing phase 2 trial of bertilimumab in bullous pemphigoid

27 Sep 2017

BRIEF-Immune Pharmaceuticals appoints Daniel Teper as CEO for Cytovia

* Immune Pharmaceuticals provides research and development and business update and summary of recent financial highlights.

28 Aug 2017

BRIEF-Immune Pharmaceuticals files for non-timely 10-Q

* Immune Pharmaceuticals Inc files for non-timely 10-Q - sec filing Source text: (http://bit.ly/2fFbJWp) Further company coverage:

15 Aug 2017

BRIEF-Immune Pharmaceuticals provides update on plan to spin-off Cytovia

* Immune Pharmaceuticals provides update on plan to implement a spin-off of Cytovia into a separate publicly traded oncology company

19 Jul 2017


Earnings vs. Estimates